Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
172.62
-1.36 (-0.78%)
At close: Nov 11, 2026, 4:00 PM EST
169.01
-3.61 (-2.09%)
Pre-market: Nov 12, 2026, 9:00 AM EST
Repligen Revenue
Repligen had revenue of $209.31M in the quarter ending September 30, 2026, with 10.86% growth. This brings the company's total for the last twelve months to $805.61M, up 13.80% year-over-year. In the year 2025, Repligen had annual revenue of $738.26M with 16.36% growth. That makes Repligen the 8,695th largest company in the world by revenue and 1,947th in the United States.
Revenue (ttm)
$805.61M
Revenue Growth
+13.80%
P/S Ratio
13.70
Revenue / Employee
$402,805
Employees
2,000
Market Cap
11.03B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Repligen breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 738.26M | 103.82M | 16.36% |
| Dec 31, 2024 | 634.44M | 2.08M | 0.33% |
| Dec 31, 2023 | 632.36M | -169.17M | -21.11% |
| Dec 31, 2022 | 801.54M | 131.00M | 19.54% |
| Dec 31, 2021 | 670.53M | 304.27M | 83.08% |
| Dec 31, 2020 | 366.26M | 96.02M | 35.53% |
| Dec 31, 2019 | 270.25M | 76.21M | 39.28% |
| Dec 31, 2018 | 194.03M | 52.80M | 37.38% |
| Dec 31, 2017 | 141.24M | 36.70M | 35.10% |
| Dec 31, 2016 | 104.54M | 21.00M | 25.14% |
| Dec 31, 2015 | 83.54M | 19.99M | 31.45% |
| Dec 31, 2014 | 63.55M | -4.62M | -6.78% |
| Dec 31, 2013 | 68.17M | 5.90M | 9.48% |
| Dec 31, 2012 | 62.27M | 34.98M | 128.16% |
| Mar 31, 2011 | 27.29M | 6.32M | 30.14% |
| Mar 31, 2010 | 20.97M | -8.39M | -28.58% |
| Mar 31, 2009 | 29.36M | 10.07M | 52.16% |
| Mar 31, 2008 | 19.30M | 5.22M | 37.10% |
| Mar 31, 2007 | 14.07M | 1.16M | 9.01% |
| Mar 31, 2006 | 12.91M | 3.55M | 37.94% |
| Mar 31, 2005 | 9.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Baxter International | 11.61B |
| Solventum | 8.16B |
| Avantor | 6.64B |
| Bausch + Lomb | 5.42B |
| The Cooper Companies | 4.24B |
| Align Technology | 4.16B |
| AptarGroup | 3.99B |
| MiniMed Group | 3.22B |
RGEN News
- 8 days ago - Repligen Corporation to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 13 days ago - Repligen to issue $1B of 0.25% Convertible Senior Notes due 2031 - TheFly
- 13 days ago - Repligen Announces $1 Billion Private Convertible Senior Notes Transaction - GlobeNewsWire
- 15 days ago - Repligen price target raised to $200 from $185 at RBC Capital - TheFly
- 16 days ago - Repligen Earnings Call Transcript: Q3 2026 - Transcripts
- 16 days ago - Repligen Earnings release: Q3 2026 - Filings
- 16 days ago - Repligen Slides: Q3 2026 - Filings
- 16 days ago - Repligen Quarterly report: Q3 2026 - Filings